Tipo |
Título / Nombre |
Autor(es) |
Año |
|
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia |
Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González AA, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P |
2019 |
|
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy |
Sánchez-Correa B, Valhondo I, Hassouneh F, López-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, Alonso C, Solana R, Tarazona R |
2019 |
|
Coexistence of ymphoplasmacytic lymphoma, multiple myeloma and myelodysplastic syndrome |
Cáceres Hernández S, Bañas Llanos H, Arcos Carmona MJ, Cardesa Cabrera R, Suárez Varela S, Casas Avilés I, Moriano Palacios B, Espina García M, Rodríguez López A, Ibañez Espacio F, Bermejo Vega N, Cabrera C, Carnicero González F, Bergua Burgués J |
2019 |
|
LMA NPM1 tras TE JAK2V617F: ¿transformación leucémica u origen de novo? |
Moriano Palacios BJ, Ferre Bermejo O, Cardesa Cabrera R, Suárez-Varela Pineda S, Cáceres Hernández S, Rodríguez López A, Espina García M, Bañas Llanos H, Arcos Carmona MJ, Ibáñez Espacio F, Bermejo Vega N, Cabrera Silva C, Prieto Fernández J, Carnicero González F, Bergua Burgués JM |
2019 |
|
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy |
Labrador J, Luño E, Vellenga E, Brunet S, González-Campos J, Chillón MC, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil C, Tormo M, Salamero O, Manso F, Fernández I, de laSerna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Cervera J, Calasanz MJ, Boluda B, Sobas M, Lowenberg B, Sanz MA, Montesinos P |
2019 |
|
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients |
Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G4, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández Campos P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P, Spanish PETHEMA group |
2019 |
|
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens |
Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, González-Campos J, Chillón M, Holowiecka A, Esteve J, Bergua J, González-Sanmiguel JD, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernández I, de la Serna J, Moreno MJ, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA, PETHEMA, HOVON, PALG, and GATLA cooperative groups |
2019 |
|
Increased survival due to lower toxicity for high-risk T-cell acute lymphoblastic leukemia patients in two consecutive pediatric-inspired PETHEMA trials |
Barba P, Morgades M, Montesinos P, Gil C, Fox ML, Ciudad J, Moreno MJ, González-Campos J, Genescà E8, Martínez-Carballeira D, Martino R, Vives S, Guardia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez-Sanchez P, Amigo ML, Bermúdez A, Calbacho M, Hernández-Rivas JM, Feliu E, Orfao A, Ribera JM |
2019 |
|
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia |
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM |
2019 |
|
Linfoma primario del sistema nervioso central y carcinoma de células renales concurrente: un caso inusual |
Moriano Palacios B, Cardesa Cabrera R, Suárez Varela Pineda S, &10, Pérez Leal F, Cáceres Hernández S, Rodríguez López Á, &10, Pisón Herrero C, Ferre Bermejo O, Bañas Llanos H, Arcos Carmona MJ, Martín Mateos ML, Ibánez Espacio F, Bermejo Vega N, Cabrera Silva C, Carnicero F, Bergua Burgués J |
2018 |